Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 9 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver DiseaseStatus unknownNCT05308160Phase 3
- Empagliflozin in Acute Heart FailureCompletedNCT05305495Phase 4
- Empagliflozin in Patients With GlomerulonephritisCompletedNCT05283057Phase 3
- Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on AnthracyclinesActive, not recruitingNCT05271162Phase 3
- TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertensionTerminatedNCT05268926Phase 2
- Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single ComponentsCompletedNCT05266404Phase 1
- Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.Status unknownNCT05262257Early Phase 1
- Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic SteatohepatitisCompletedNCT05254626Phase 2
- Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis TreatmentStatus unknownNCT05250752Phase 2
- Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis InterventionStatus unknownNCT05241431Phase 2/3
- Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed ConditionsCompletedNCT05229796Not applicable
- Short-term Use of Dapagliflozin to Protect Kidney Function in CKD PatientsStatus unknownNCT05225077Phase 4
- Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial DysfunctionStatus unknownNCT05217654Phase 1
- SGLT2 Inhibition: Uric Acid Excretion StudyCompletedNCT05210517Phase 4
- Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various EthnicitiesStatus unknownNCT05207176Phase 1
- Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary SyndromeStatus unknownNCT05200793Phase 4
- Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney DiseaseCompletedNCT05196347Phase 3
- A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy VolunteersCompletedNCT05192395Phase 1
- Empagliflozin in Hypertrophic CardiomyopathyActive, not recruitingNCT05182658Phase 3
- SGLT2 Inhibition in HemodialysisCompletedNCT05179668Phase 2
- Dapagliflozin in Pulmonary Arterial HypertensionCompletedNCT05179356Phase 2
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With PrediabetesWithdrawnNCT05174507Phase 2
- ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEFCompletedNCT05152940Phase 4
- Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B PatientsActive, not recruitingNCT05147090Phase 4
- The Safety of Dapagliflozin in Hemodialysis Patients With Heart FailureStatus unknownNCT05141552Not applicable
- Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection FractionCompletedNCT05139472Phase 4
- Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.Status unknownNCT05135039Not applicable
- Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)CompletedNCT05132023Phase 1
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two DiabetesStatus unknownNCT05109949Phase 3
- ADME Study of [14C]- Rongliflozin in Healthy Male SubjectsCompletedNCT05109078Phase 1
- The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart FailureCompletedNCT05084235Phase 2
- Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 DeficiencyCompletedNCT05078879Phase 1
- Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in CystinuricsWithdrawnNCT05058859Phase 2
- Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative ColitisWithdrawnNCT05058417Phase 2
- Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric BypassCompletedNCT05057819Phase 4
- Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial InfarctionCompletedNCT05050500Phase 4
- The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic DysfunctionStatus unknownNCT05045274Not applicable
- The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart FailureCompletedNCT05042973Phase 2
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver TransplantationCompletedNCT05042505Not applicable
- SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)Status unknownNCT05037695Phase 4
- Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of EmpagliflozinCompletedNCT05036421Phase 3
- ORAL ANTIDIABETICS EFFECT ON VISCERAL FATStatus unknownNCT05032001Not applicable
- Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast CancerStatus unknownNCT05025735Phase 2
- EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial InfarctionActive, not recruitingNCT05020704Phase 3
- Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCTStatus unknownNCT05014594Phase 2
- Empagliflozin in Diuretic Refractory AscitesCompletedNCT05013502Phase 1
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)CompletedNCT05013112Not applicable
- Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy ParticipantsCompletedNCT04991571Phase 1
- Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty LiverStatus unknownNCT04976283Phase 4
- Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney DiseaseStatus unknownNCT04961931Not applicable
- Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart FailureCompletedNCT04956809Phase 2
- Safety and Efficacy of Empagliflozin in GSD1b Patients With NeutropeniaStatus unknownNCT04930627Phase 2
- Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)CompletedNCT04930549Phase 2
- The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis PatientsCompletedNCT04923295Not applicable
- Effects of Empagliflozin in Reducing Oxidative Stress After Kidney TransplantationCompletedNCT04918407Not applicable
- Empagliflozin in Adolescent DiabetesWithdrawnNCT04917692Phase 4
- Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone FormersCompletedNCT04911660Phase 2
- Follow-up of NAFLD Patients With MRI-PDFFCompletedNCT04910178Phase 4
- Neoadjuvant SGLT2 Inhibition in Localized Prostate CancerTerminatedNCT04887935Phase 1
- Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent CongestionStatus unknownNCT04882358Not applicable
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed ConditionsCompletedNCT04881006Phase 1
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting ConditionsCompletedNCT04880993Phase 1
- Dapagliflozin on Volume Vascular Outcomes.CompletedNCT04869124Phase 4
- DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceStatus unknownNCT04860011Phase 3
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult VolunteersCompletedNCT04856969Phase 1
- A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.CompletedNCT04856007Phase 1
- Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary InterventionStatus unknownNCT04806633Early Phase 1
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialStatus unknownNCT04796428Phase 4
- Dapagliflozin in Non-diabetic Stage IV CKDCompletedNCT04794517Phase 2
- Effect of Dapagliflozin on LV Remodeling Post AMIStatus unknownNCT04783870Phase 4
- Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting ListWithdrawnNCT04782245Phase 2
- Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.Status unknownNCT04780438Early Phase 1
- Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal DiseaseWithdrawnNCT04764097Phase 2/3
- EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.CompletedNCT04743453Phase 4
- Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEFStatus unknownNCT04739215Phase 4
- Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)Status unknownNCT04720859Not applicable
- Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)CompletedNCT04717986Not applicable
- Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .CompletedNCT04707352Phase 3
- Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASHStatus unknownNCT04702490Phase 2
- SGLT2 Inhibitors in Patients With PCOSCompletedNCT04700839Phase 4
- Dapagliflozin After Transcatheter Aortic Valve ImplantationCompletedNCT04696185Phase 4
- Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes MellitusCompletedNCT04665284Phase 4
- The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes MellitusCompletedNCT04654390Phase 3
- Effect of Empagliflozin on Liver Fat in Non-diabetic PatientsCompletedNCT04642261Phase 4
- SGLT2-Inhibitors for Sleep Apnea in Heart FailureWithdrawnNCT04640493Phase 2
- Combined Active Treatment in Type 2 Diabetes With NASHCompletedNCT04639414Phase 4
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.CompletedNCT04634500Phase 3
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.CompletedNCT04632862Phase 3
- Dapagliflozin Treatment in Type 2 DiabetesCompletedNCT04620590Phase 4
- The DAPA-MEMRI TrialCompletedNCT04591639Not applicable
- Empagliflozin and Atrial Fibrillation TreatmentStatus unknownNCT04583813Phase 4
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan TherapyCompletedNCT04575675Phase 4
- Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®Status unknownNCT04570865Phase 4
- Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)Active, not recruitingNCT04541797Not applicable
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialCompletedNCT04535960Phase 2
- Efficacy and Safety of Dapagliflozin in Children With ProteinuriaCompletedNCT04534270Phase 4
- POST-CABGDM: Empagliflozin in Perioperative CABGCompletedNCT04523064Phase 4
- A Pilot Study of Empagliflozin in the Treatment of Acromegalic CardiomyopathyStatus unknownNCT04520646Not applicable
- Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary InterventionsCompletedNCT04497792Phase 4
- Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)Status unknownNCT04490681Phase 3